LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Search

Quidel Corp

Geschlossen

27.38 -2.74

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

27.38

Max

28.02

Schlüsselkennzahlen

By Trading Economics

Angestellte

6,600

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+25.82% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

5.6M

1.6B

Vorheriger Eröffnungskurs

30.12

Vorheriger Schlusskurs

27.38

Quidel Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Nov. 2025, 16:49 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27. Nov. 2025, 15:32 UTC

Akquisitionen, Fusionen, Übernahmen

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27. Nov. 2025, 23:50 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27. Nov. 2025, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. Nov. 2025, 16:05 UTC

Market Talk

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27. Nov. 2025, 16:04 UTC

Market Talk

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27. Nov. 2025, 15:54 UTC

Akquisitionen, Fusionen, Übernahmen

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27. Nov. 2025, 15:44 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27. Nov. 2025, 15:43 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27. Nov. 2025, 15:42 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27. Nov. 2025, 15:41 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27. Nov. 2025, 15:11 UTC

Market Talk

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27. Nov. 2025, 14:26 UTC

Market Talk

Hermes' Outperformance Gap Could Narrow -- Market Talk

27. Nov. 2025, 14:11 UTC

Market Talk

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27. Nov. 2025, 14:11 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27. Nov. 2025, 13:35 UTC

Market Talk

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27. Nov. 2025, 13:33 UTC

Market Talk

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27. Nov. 2025, 13:22 UTC

Market Talk

Global Equities Roundup: Market Talk

27. Nov. 2025, 13:22 UTC

Market Talk

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27. Nov. 2025, 13:17 UTC

Market Talk

LVMH Should Be Able to Recover Next Year -- Market Talk

27. Nov. 2025, 11:13 UTC

Market Talk

European Gas Prices Come Under Pressure -- Market Talk

27. Nov. 2025, 11:07 UTC

Ergebnisse

Genting: Positive About Prospects Over Longer Term

27. Nov. 2025, 11:06 UTC

Ergebnisse

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27. Nov. 2025, 11:04 UTC

Ergebnisse

Genting: International Travel Demand Expected to Remain Resilient

27. Nov. 2025, 11:04 UTC

Ergebnisse

Genting: Global Growth Expected to Remain Subdued

27. Nov. 2025, 11:04 UTC

Ergebnisse

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27. Nov. 2025, 10:59 UTC

Ergebnisse

Genting Bhd 3Q Net Profit Fell 86% on Year

27. Nov. 2025, 10:58 UTC

Ergebnisse

Genting Bhd 3Q Rev Rose 14% on Year

27. Nov. 2025, 10:56 UTC

Ergebnisse

Genting Bhd 3Q Net MYR30.3M

27. Nov. 2025, 10:56 UTC

Ergebnisse

Genting Bhd 3Q EPS MYR0.0079

Peer-Vergleich

Kursveränderung

Quidel Corp Prognose

Kursziel

By TipRanks

25.82% Vorteil

12-Monats-Prognose

Durchschnitt 34.6 USD  25.82%

Hoch 62 USD

Tief 22 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Quidel Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

3

Buy

3

Halten

1

Sell

Finanzen

$

Über Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat